Tombot Raises $7M Series A3 to Expand Companion Robotics

Technology spends a lot of time trying to make humans faster. Tombot is pursuing something less obvious and arguably more difficult. The Santa Clarita, California-based robotics company has closed a $7M Series A3 growth financing round to expand operations, grow its companion robotics portfolio, and move its flagship robotic puppy, Jennie, closer to broader commercialization. Investors participating in the round include Caduceus Capital Partners, Wavemaker 360, The Lutheran Foundation for Long Term Living, and Florida Community Health Network.

The funding is more than another venture capital headline. It reflects growing investor confidence that emotional wellbeing, aging, and assistive robotics are converging into a meaningful market rather than remaining isolated healthcare niches. Tombot is positioning itself where robotics, digital health, eldercare, and behavioral health increasingly overlap. For founders, investors, healthcare providers, and technology operators, this announcement signals that capital continues to move toward companies solving deeply human problems instead of simply automating existing workflows.

What Happened

Tombot announced the close of a $7M Series A3 growth financing round on June 24, 2026. Rather than identifying a single lead investor, the company announced participation from Caduceus Capital Partners, Wavemaker 360, The Lutheran Foundation for Long Term Living, and Florida Community Health Network. The proceeds will support operational scaling, expansion of Tombot's companion robotics product line, and commercialization efforts surrounding Jennie.

The company previously announced a $6.1M Series A financing in 2025. While Tombot has referenced higher cumulative capital raised through its own investor materials, the publicly confirmed later-stage financings documented in the research packet include the 2025 Series A and the new $7M Series A3 round. No valuation was disclosed.

Tombot was launched in 2017 by Co-Founder and CEO Tom Stevens. According to the company's story, the idea originated from Stevens' experience caring for his mother after Alzheimer's disease prevented her from safely owning a live dog. Co-Founder and CTO Hank Schorz helped transform that mission into a robotics platform focused on companionship rather than novelty.

Why Tombot Is Different

Jennie is intentionally designed to resemble an 8-to-10-week-old Labrador puppy. The robotic companion responds to voice, touch, and movement while exhibiting lifelike behaviors intended to provide emotional comfort for individuals who cannot care for live animals.

The target audience extends well beyond traditional consumer robotics. Tombot focuses on older adults living with dementia while also addressing broader behavioral health populations, including people experiencing anxiety, loneliness, autism, or PTSD. Company materials also position Jennie as a solution for individuals restricted from pet ownership because of health conditions, living arrangements, or caregiving limitations.

The technical vision combines interactive sensors, voice commands, rechargeable operation, authentic puppy sounds, and software updates within a highly realistic physical design. Tombot also credits Jim Henson's Creature Shop with contributing to Jennie's animatronic artistry. While the company discusses patent-pending behaviors and long-term FDA ambitions, the supplied research does not indicate current FDA clearance or approval.

Why This Funding Matters

Healthcare innovation is increasingly expanding beyond diagnostics, software, and clinical workflows. Emotional wellbeing, caregiver support, and healthy aging have become investable infrastructure. That shift becomes easier to understand when viewed through demographic realities rather than technology trends: aging populations continue to grow, caregiver shortages remain persistent, loneliness has become an increasingly recognized health concern, and families often struggle to balance caregiving responsibilities with everyday life.

Against that backdrop, Tombot is building technology designed to supplement emotional connection rather than replace human relationships. That distinction gives the company a differentiated position within digital health and companion robotics. Investor participation also reinforces this direction, because the organizations supporting Tombot reflect interests across healthcare innovation, long-term care, and community health rather than traditional consumer electronics alone.

Market Context

One of the strongest indicators of early product-market fit is customer commitment before broad commercialization. According to Tombot investor materials and the research packet, the company reports substantial pre-order and waitlist demand ahead of customer launch, including references to more than 23,000 pre-orders and waitlist sign-ups and demand spanning more than 116 countries.

Those figures should not be viewed simply as reservation numbers. They suggest meaningful demand for technologies addressing companionship, dementia care, and behavioral health support. Unlike many robotics companies pursuing industrial automation or warehouse efficiency, Tombot is operating within an emerging category where emotional outcomes are central to product value.

What This Signals for the Robotics Industry

Robotics investment has traditionally favored productivity gains, manufacturing efficiency, and logistics optimization. Companion robotics introduces a different investment thesis: instead of asking whether robots can replace human labor, companies like Tombot ask whether technology can meaningfully improve quality of life.

That question carries significant commercial implications. Products supporting healthy aging, caregiver resilience, and emotional wellbeing increasingly sit at the intersection of healthcare, robotics, and consumer technology. Investors appear willing to fund companies capable of building products that serve all three markets simultaneously. If commercialization unfolds as planned, Tombot's Series A3 financing may represent more than growth capital. It may reflect broader confidence that companion robotics is evolving into a durable category within digital health.